Rocket Pharmaceuticals, Inc.
RCKT
$8.32
-$0.14-1.66%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 25.34M | 27.11M | 27.37M | 22.15M | 18.54M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 62.69M | 69.42M | 73.71M | 67.38M | 60.28M |
| Operating Income | -62.69M | -69.42M | -73.71M | -67.38M | -60.28M |
| Income Before Tax | -60.33M | -66.72M | -69.65M | -62.05M | -59.66M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -60.33M | -66.72M | -69.65M | -62.05M | -59.66M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -60.33M | -66.72M | -69.65M | -62.05M | -59.66M |
| EBIT | -62.69M | -69.42M | -73.71M | -67.38M | -60.28M |
| EBITDA | -60.33M | -67.04M | -71.34M | -65.12M | -58.34M |
| EPS Basic | -0.62 | -0.71 | -0.74 | -0.66 | -0.64 |
| Normalized Basic EPS | -0.39 | -0.46 | -0.48 | -0.43 | -0.40 |
| EPS Diluted | -0.62 | -0.71 | -0.74 | -0.66 | -0.64 |
| Normalized Diluted EPS | -0.39 | -0.46 | -0.48 | -0.43 | -0.40 |
| Average Basic Shares Outstanding | 97.53M | 94.16M | 93.75M | 93.55M | 93.34M |
| Average Diluted Shares Outstanding | 97.53M | 94.16M | 93.75M | 93.55M | 93.34M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
